Extraintestinal Manifestations of Inflammatory Bowel Disease (IBD): Joints, Skin, Eyes, Liver

Extraintestinal Manifestations Joints Skin Eyes — scientific infographic poster

The Gut Is Not the Whole Disease
Peripheral Arthritis — Type 1 and Type 2
Axial Spondyloarthritis and Ankylosing Spondylitis Overlap
Erythema Nodosum
Pyoderma Gangrenosum
Aphthous Stomatitis and Other Oral Lesions
Uveitis, Episcleritis, and Scleritis
Primary Sclerosing Cholangitis (PSC)
Metabolic Bone Disease — Osteopenia and Osteoporosis
Thromboembolism Risk During Flares
Treatment Overlap — One Drug, Many Problems
Red Flags — When to Call Someone Today
Key Research Papers
Connections
Featured Videos

The Gut Is Not the Whole Disease

Inflammatory bowel disease is named for the bowel, but for roughly 25–40% of patients the disease also shows up somewhere else: joints that swell, skin that ulcerates, eyes that go red and painful, or a liver whose bile ducts slowly scar. These are called extraintestinal manifestations (EIMs), and they matter for three reasons.

First, some EIMs appear before bowel symptoms and can be the clue that gets you diagnosed at all. A young adult with recurrent painful red eyes or a stubborn shin ulcer plus intermittent diarrhea may spend years bouncing between specialists before anyone orders a calprotectin test. Second, some EIMs — primary sclerosing cholangitis is the headline example — carry their own cancer and transplant risks that have almost nothing to do with how bad your colitis feels today. Third, the choice of inflammatory bowel disease (IBD) drug often hinges on which EIMs you have. Anti-tumor necrosis factor (anti-TNF) biologics treat gut and joints and uveitis and pyoderma in one shot. Vedolizumab (gut-selective) is excellent for the bowel but weaker on joints and skin. Janus kinase (JAK) inhibitors help some EIMs and worsen others. See the biologics article for the drug-by-drug breakdown.

A 2021 review in Gastroenterology reports that extraintestinal manifestations appear before any gut symptoms in up to 24% of people with inflammatory bowel disease. Peripheral arthritis, mouth ulcers (oral aphthous ulcers), episcleritis and erythema nodosum tend to go with active gut inflammation and can improve with standard treatment of the gut, while anterior uveitis, ankylosing spondylitis and primary sclerosing cholangitis usually run independently of flares.

This page walks through each of the big EIMs: what it looks like, how fast you need to move, and how treatment decisions interlock with your inflammatory bowel disease plan.

Peripheral Arthritis — Type 1 and Type 2

Joint inflammation is the most common EIM in inflammatory bowel disease, affecting 15–30% of patients at some point. Rheumatologists split inflammatory bowel disease peripheral arthritis into two distinct patterns, and the distinction actually matters for treatment.

Type 1 (Pauciarticular) — The Flare Companion

Few joints — fewer than five, usually large (knee, ankle, wrist, elbow).
Asymmetric — one knee but not the other.
Acute attacks that last days to a few weeks.
Parallels bowel activity — joints flare when the colon flares, settle when the colon settles.
Non-erosive — does not damage the joint permanently.

Type 1 is essentially a symptom of uncontrolled gut inflammation. Treating the bowel usually treats the joints. When inflammatory bowel disease therapy is stepped up (corticosteroid taper, biologic, or immunomodulator) and the colitis goes into remission, the knees and ankles calm down with it. Nonsteroidal anti-inflammatory drugs (NSAIDs) can help symptomatically but carry a real risk of triggering bowel flares, which is why only short courses are used. Intra-articular steroid injections are a safer bridge for a single hot joint.

Type 2 (Polyarticular) — The Independent One

Many joints — five or more, often small (the knuckles where the fingers join the hand, called metacarpophalangeal joints; the middle finger joints, called proximal interphalangeal joints; and the wrists).
Symmetric — both hands look the same.
Chronic — months to years, often lifelong.
Independent of bowel activity — can flare while the colon is in total remission.
Usually non-erosive but can occasionally cause damage.

Type 2 behaves more like its own rheumatologic disease. Controlling the gut alone is not enough. Treatment leans on anti-TNF biologics (infliximab, adalimumab), which target both inflammations at once, or sulfasalazine, which has mild activity in both bowel and joints. Methotrexate is an option if the inflammatory bowel disease is Crohn's (it has bowel evidence) and weaker if the inflammatory bowel disease is ulcerative colitis. Rheumatology co-management is usually needed.

Axial Spondyloarthritis and Ankylosing Spondylitis Overlap

Separately from peripheral arthritis, 5–10% of inflammatory bowel disease patients develop inflammation of the spine and sacroiliac joints — what rheumatologists now call axial spondyloarthritis, with ankylosing spondylitis as the radiographic-stage endpoint. The hallmark symptom is inflammatory back pain: worse at rest, wakes you in the second half of the night, stiffness over an hour in the morning, and — critically — better with movement rather than worse. If your back hurts most after walking, it is probably mechanical. If it hurts most when you wake up and loosens with activity, it is inflammatory.

The genetic marker human leukocyte antigen-B27 is positive in roughly 50–70% of inflammatory bowel disease-associated axial disease — lower than in classical ankylosing spondylitis (AS) (90–95%) but still far above general-population rates. See the human leukocyte antigen-B27 article and the ankylosing spondylitis and inflammatory bowel disease overlap article for the full explanation of how these diseases share genetics and gut-driven immunity.

Axial disease is independent of bowel activity — like Type 2 peripheral arthritis. Your back can fuse slowly while your colon looks pristine on colonoscopy. That is why treatment selection matters:

Anti-TNF biologics (infliximab, adalimumab, golimumab, certolizumab) treat both gut and spine. First choice when both are active.
Interleukin-17 (IL-17) inhibitors (secukinumab, ixekizumab) work beautifully for ankylosing spondylitis but can worsen or trigger inflammatory bowel disease, so they are generally not used in people with known inflammatory bowel disease.
The interleukin-23 (IL-23) inhibitor risankizumab and the interleukin-12/23 (IL-12/23) inhibitor ustekinumab treat Crohn's disease; ustekinumab also has modest evidence in psoriatic and axial spondyloarthritis.
Vedolizumab (gut-selective integrin blocker) does not reach the spine and generally does not treat axial disease — some patients even develop new joint symptoms on it.
Nonsteroidal anti-inflammatory drugs are ankylosing spondylitis first-line but can aggravate inflammatory bowel disease. The usual practice is the lowest effective dose for the shortest duration, often with a cyclooxygenase-2 (COX-2) selective agent (celecoxib) when tolerated.

The ankylosing spondylitis overview covers imaging (magnetic resonance imaging (MRI) sacroiliac joints before X-ray changes appear), physical-therapy protocols, and the full rheumatologic workup.

Erythema Nodosum

Erythema nodosum (EN) is the more common of the two classic inflammatory bowel disease skin lesions, affecting roughly 3–15% of patients. It looks like tender, warm, red-to-purple nodules typically 1–5 cm across, most often on the shins but sometimes on thighs, forearms, or trunk. They feel bruised and hot; pressing them hurts.

EN tracks gut activity closely. Lesions appear during flares and fade as the flare resolves, usually over 3–6 weeks, often leaving a transient bruise-like discoloration but no scar. New crops during active colitis are common.

Treatment centres on the bowel. Rest, leg elevation, and cool compresses help with pain. Nonsteroidal anti-inflammatory drugs relieve tenderness but again carry bowel-flare risk, so only short courses are used. Stubborn, painful EN that does not respond to gut control may warrant systemic corticosteroids or escalation to a biologic, decisions that usually match the gastroenterologist's plan for the colon anyway.

EN is not specific to inflammatory bowel disease. Strep throat, sarcoidosis, tuberculosis, pregnancy, oral contraceptives, and certain drugs can trigger it. First-time EN is usually worked up with a chest X-ray (for sarcoidosis and tuberculosis) and a strep swab, even in a patient with known inflammatory bowel disease.

Pyoderma Gangrenosum

Pyoderma gangrenosum (PG) is rarer than EN (1–5% of inflammatory bowel disease patients) and far more serious. It begins as a small painful pustule or bump — often mistaken for an insect bite or minor wound — that rapidly breaks down into a deep, necrotic ulcer with a characteristic violaceous (purple) undermined border. The pain is disproportionate to what the lesion looks like; patients describe it as burning or searing. Lesions favor the legs but can appear anywhere, including around stoma sites (peristomal pyoderma).

Three pitfalls:

Pathergy. PG can be triggered or worsened by surgical debridement. The instinct to cut away the dead tissue is wrong. A surgeon who does not recognize PG can convert a 3 cm ulcer into a 20 cm one. A wound that is expanding rapidly with a purple border and hurts far more than it should is the pattern that raises PG before any operation.
Activity independence. Unlike erythema nodosum, PG does not reliably parallel bowel activity. It can flare when your colitis is quiet.
Diagnosis is clinical and one of exclusion. There is no confirmatory biopsy finding — biopsy is done mainly to rule out infection, vasculitis, and malignancy.

Treatment escalates with severity:

Topical or intralesional corticosteroids / tacrolimus for small, early lesions.
Systemic corticosteroids (prednisone 0.5–1 mg/kg/day) for larger or spreading disease, usually with rapid response.
Cyclosporine as a steroid-sparing alternative.
Biologics — especially infliximab — are the modern game-changer. In the first placebo-controlled trial of any drug for PG (Brooklyn et al., 2006), 30 patients received one infusion of infliximab 5 mg/kg or a placebo: at week 2, 46% (6 of 13) had improved on infliximab versus 6% (1 of 17) on placebo. Non-responders were then offered open-label infliximab; of the 29 patients who received it, 69% responded and 21% were in remission at week 6. Adalimumab, ustekinumab, and JAK inhibitors have also shown benefit in case series.

Peristomal PG around an ostomy site is particularly frustrating because pouching systems chronically traumatize the skin and perpetuate pathergy. Stoma nurses experienced with PG, convex wafers, and anti-inflammatory therapy are essential. See the surgery decisions article for more on ostomy care.

Aphthous Stomatitis and Other Oral Lesions

Painful mouth ulcers are one of the most under-recognized inflammatory bowel disease manifestations. Up to 20–50% of patients with Crohn's disease and 10% of those with ulcerative colitis develop recurrent aphthae — small (2–10 mm), round, yellow-white ulcers with red halos on the inside of the lips, cheeks, or tongue. They sting with acidic foods and usually heal in 7–14 days without scarring. They often flare with the bowel.

More Crohn's-specific oral findings include cobblestone mucosa (lumpy, fissured buccal surface), deep linear ulcers, pyostomatitis vegetans (a snail-track pustular lesion seen mainly in ulcerative colitis (UC)), and angular cheilitis from iron, B12, or folate deficiency — see the nutrient deficiencies article.

Management is mostly symptomatic: topical anesthetics (lidocaine viscous), topical corticosteroids (triamcinolone in orabase, dexamethasone rinse), and treatment of the underlying inflammatory bowel disease. Severe or persistent Crohn's oral disease responds to systemic biologics, just like the gut.

Uveitis, Episcleritis, and Scleritis

Eye involvement affects 2–10% of inflammatory bowel disease patients and ranges from nuisance to sight-threatening. The three main patterns differ in how fast you need to move.

Episcleritis — Uncomfortable, Not Dangerous

Inflammation of the thin vascular layer just under the conjunctiva. The eye looks pink or red in a wedge-shaped patch, feels gritty or mildly achy but not deeply painful, and vision is normal. Episcleritis mirrors bowel activity and usually settles with topical lubricants or a short topical nonsteroidal anti-inflammatory drug (NSAID) drop. Treating the flare resolves it. Not sight-threatening.

Scleritis — Deep, Painful, Serious

Inflammation of the deeper scleral wall. The eye is deeply red with a bluish or purplish tint, the pain is severe and boring (wakes you at night, radiates to the forehead or jaw), and vision may be blurred. Scleritis can thin the sclera and, in rare cases, perforate the eye. This is a same-day ophthalmology referral, not a "next available appointment." Treatment usually requires systemic nonsteroidal anti-inflammatory drugs, systemic corticosteroids, and often a biologic.

Uveitis — The Sight-Threatening One

Inflammation of the uveal tract (iris, ciliary body, choroid). Inflammatory bowel disease-associated uveitis is typically anterior (iritis), often bilateral, insidious, and chronic — different from the classical human leukocyte antigen-B27 ankylosing spondylitis-pattern uveitis, which is unilateral, acute, and alternates eyes.

Red-flag symptoms:

Eye pain (often worse with bright light)
Photophobia so severe you squint in normal room light
Blurred vision or floaters
Circumlimbal redness (ciliary flush) — the redness ringed tightly around the cornea, not diffuse
Pupil that looks small, irregular, or sluggish

Any of these is treated as needing same-day ophthalmology evaluation. Untreated uveitis causes synechiae (iris stuck to the lens), glaucoma, cataract, macular edema, and permanent vision loss. Treatment includes topical corticosteroid drops, cycloplegic drops (to prevent synechiae), and in refractory cases systemic corticosteroids or anti-TNF biologics. Infliximab and adalimumab have strong evidence in non-infectious uveitis.

In a person with inflammatory bowel disease, a red eye with pain or light sensitivity is a sign that emergency departments and ophthalmologists treat as same-day urgent; delay risks permanent vision loss.

Primary Sclerosing Cholangitis (PSC)

PSC is the most serious extraintestinal manifestation of inflammatory bowel disease. It is a chronic, progressive inflammation and scarring of the intra- and extrahepatic bile ducts. Roughly 70–80% of PSC patients have inflammatory bowel disease, overwhelmingly ulcerative colitis (pancolitis pattern, often with backwash ileitis and rectal sparing). Conversely, only 2–8% of inflammatory bowel disease patients develop PSC — but those who do face a very different long-term prognosis.

How It Presents

Many patients are discovered incidentally through abnormal liver blood tests — a persistently elevated alkaline phosphatase (ALP), often 2–3 times the upper limit of normal, with less elevated aspartate aminotransferase (AST)/alanine aminotransferase (ALT). Gamma-glutamyl transferase (GGT) is usually up, bilirubin is often normal early on. Others present with fatigue, pruritus (itching), right-upper-quadrant pain, or jaundice. Some present with bacterial cholangitis: fever, chills, abdominal pain — a medical emergency.

Screening in Inflammatory Bowel Disease

Current guidance from the American Association for the Study of Liver Diseases (AASLD) and the American College of Gastroenterology (ACG) supports annual liver function tests in everyone with inflammatory bowel disease. If alkaline phosphatase is persistently elevated with no other explanation, the next step is MRCP (magnetic resonance cholangiopancreatography) — a non-invasive magnetic resonance imaging of the bile ducts that shows the characteristic beaded or pruned-tree pattern of strictures and dilations. Endoscopic retrograde cholangiopancreatography (ERCP) is reserved for diagnosis when MRCP is equivocal or when a dominant stricture needs intervention.

Cholangiocarcinoma and Colon Cancer Risk

PSC dramatically raises two cancer risks, and both change your surveillance schedule:

Cholangiocarcinoma. Lifetime risk is roughly 10–15% in PSC patients, compared to essentially zero in the general population. Annual surveillance with MRI/MRCP plus CA 19-9 is typical, though the optimal strategy remains debated.
Gallbladder cancer. Elevated risk; any gallbladder polyp in PSC is generally a reason for cholecystectomy regardless of size.
Colorectal cancer. PSC plus ulcerative colitis is the highest-risk combination in inflammatory bowel disease. Surveillance colonoscopy every year from the time of PSC diagnosis, not the standard 1–3-year intervals used for UC without PSC. Chromoendoscopy or high-definition white-light with targeted biopsies is preferred.

Treatment

There is no proven disease-modifying medical therapy for PSC. Ursodeoxycholic acid at moderate doses (13–15 mg/kg/day) is widely used and improves liver numbers, but high doses paradoxically worsen outcomes and are avoided. Inflammatory bowel disease biologics control the colon but do not halt bile-duct disease. Dominant strictures can sometimes be dilated endoscopically. The only cure for advanced PSC is liver transplantation, with generally excellent outcomes, though PSC can recur in the graft.

A PSC diagnosis does not mean imminent disaster — many patients live decades with slowly progressive disease — but it does change the surveillance intensity and the overall risk picture. Care for confirmed PSC usually involves a hepatologist (liver specialist), not just a gastroenterologist.

Metabolic Bone Disease — Osteopenia and Osteoporosis

Bone loss is common and under-diagnosed in inflammatory bowel disease. Roughly 30–50% of inflammatory bowel disease patients have osteopenia and 15% have frank osteoporosis. The drivers stack up:

Chronic systemic inflammation — cytokines (tumor necrosis factor and interleukin-6 (IL-6)) directly activate bone-resorbing osteoclasts.
Corticosteroid exposure — any cumulative prednisone burden raises fracture risk; this is the single most modifiable factor.
Vitamin D and calcium malabsorption, especially in Crohn's disease of the small bowel or after resection.
Low body weight, undernutrition, and hypogonadism from chronic illness.
Reduced weight-bearing activity during flares.

A baseline bone density scan (dual-energy X-ray absorptiometry, DEXA) is commonly done for inflammatory bowel disease patients with a significant steroid course (≥3 months of prednisone equivalent), postmenopausal status, low body mass index (BMI), or chronic active disease, and repeated every 1–2 years as indicated. Management includes:

Adequate calcium (1000–1200 mg/day) and vitamin D (target 25-OH-D above 30 ng/mL).
Weight-bearing and resistance exercise.
Smoking cessation, moderate alcohol.
Minimizing cumulative steroid exposure — a major argument for starting biologics sooner.
Bisphosphonates (alendronate, zoledronic acid) for established osteoporosis or T-score ≤ -1.5 on chronic steroids.

Thromboembolism Risk During Flares

One of the most dangerous and least-recognized EIMs is not a visible lesion at all — it is a blood clot. Active inflammatory bowel disease is a hypercoagulable state. In a 2010 cohort study of 13,756 people with inflammatory bowel disease and 71,672 matched controls, people with inflammatory bowel disease had a 3.4-fold higher risk of venous thromboembolism (VTE) — deep-vein thrombosis and pulmonary embolism — overall (2.6 clots per 1,000 person-years). At the time of a flare the risk was 8.4-fold higher (9.0 per 1,000 person-years). The relative jump was largest in flares outside hospital (15.8-fold; 6.4 per 1,000 person-years), while the absolute rate was highest during hospitalized flares (37.5 per 1,000 person-years). The authors called for trials of preventive treatment. The risk persists for months after the flare resolves.

Implications:

European consensus and American College of Gastroenterology guidance recommend drug prevention of deep vein thrombosis (DVT) for hospitalized inflammatory bowel disease patients (heparin or low-molecular-weight heparin, LMWH) unless they are actively hemorrhaging; bloody stools alone are not treated as a reason to withhold it.
The signs of deep vein thrombosis are one-sided calf swelling, warmth and tenderness; the signs of pulmonary embolism (PE) are sudden shortness of breath, pleuritic chest pain, unexplained tachycardia and fainting (syncope). Any of these during or shortly after a flare is an emergency.
Estrogen-containing contraceptives add their own clot risk on top of a severe flare; progestin-only options and intrauterine devices (IUDs) are the alternatives usually considered for that reason.
For long-distance travel during a flare, extra hydration, calf exercises, and compression stockings are commonly used. Some clinicians recommend prophylactic LMWH for flights over 6–8 hours in actively flaring patients.
The JAK inhibitor class (tofacitinib, upadacitinib) carries a boxed warning for VTE. That risk is weighed against the thromboembolic risk of uncontrolled flares — see the article on JAK inhibitors and sphingosine-1-phosphate (S1P) modulators.

Treatment Overlap — One Drug, Many Problems

Because multiple EIMs share inflammatory pathways with the gut, well-chosen inflammatory bowel disease therapy can collapse several problems into one prescription. A rough map:

Anti-TNF (infliximab, adalimumab). Excellent for gut + peripheral arthritis (both types) + axial disease + uveitis + pyoderma gangrenosum + erythema nodosum. The broadest EIM coverage of any class.
Ustekinumab (IL-12/23). Good for gut + psoriasis + peripheral arthritis; modest for axial disease.
Risankizumab / Mirikizumab (IL-23). Strong gut efficacy; emerging data for skin and joint EIMs.
Vedolizumab (gut-selective). Excellent gut safety, poor EIM coverage. It is often combined with targeted EIM therapy (topical eye drops, local injections), or replaced by another class when EIMs dominate.
Tofacitinib / Upadacitinib (JAK). Helpful for gut + peripheral arthritis + axial disease + pyoderma. Known risks include VTE, shingles (zoster) and lipid changes.
Sulfasalazine. Mild gut + peripheral joint coverage; cheap, old, still useful for overlap cases.
Drugs that can worsen inflammatory bowel disease: IL-17 inhibitors (secukinumab, ixekizumab) can trigger or worsen colitis. Nonsteroidal anti-inflammatory drugs can trigger flares, which is why they are used briefly and cautiously.

Red Flags — When to Call Someone Today

Most EIMs are chronic annoyances. A few are same-day emergencies:

Red, painful eye with light sensitivity or blurred vision — same-day ophthalmology.
Rapidly expanding, painful skin ulcer with a purple border — possible pyoderma gangrenosum; debridement before PG is ruled out can make it much larger.
Unilateral leg swelling, warmth, and tenderness — possible deep vein thrombosis; emergency evaluation.
Sudden shortness of breath, pleuritic chest pain, unexplained tachycardia, or fainting — possible pulmonary embolism; a 911 emergency.
Fever + jaundice + right-upper-quadrant pain — possible bacterial cholangitis in PSC; emergency department.
New-onset severe, progressive back pain with bowel or bladder changes — cauda equina (rare) or spinal fracture in osteoporotic inflammatory bowel disease patients needs ruling out.

Less clear cases are handled by the gastroenterology team or urgent care; inflammatory bowel disease patients have good reason for a low threshold.

Key Research Papers

Rogler G, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021. — doi:10.1053/j.gastro.2021.07.042
Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998. — doi:10.1136/gut.42.3.387 (Type 1 vs Type 2 classification)
Brooklyn TN, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo-controlled trial. Gut. 2006. — doi:10.1136/gut.2005.074815
Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023. — doi:10.1002/hep.32771
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010. — doi:10.1016/s0140-6736(09)61963-2
Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–254. — doi:10.1093/ecco-jcc/jjv213

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on inflammatory bowel disease extraintestinal manifestations:

Back to Table of Contents